Cardiovascular Safety Results for Anemia Drug Disappoint Cardiovascular Safety Results for Anemia Drug Disappoint

Vadadustat did not meet the noninferiority criteria for cardiovascular safety in the PRO2TECT studies that compared the HIF inhibitor with an erythropoiesis-stimulating agent.Medscape Medical News

Source: Medscape Today Headlines - October 26, 2020 Category: Consumer Health News Tags: Nephrology News Video Source Type: news